Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for Lucid Diagnostics (LUCD) over the last 4 years, with Q3 2025 value amounting to $1.2 million.

  • Lucid Diagnostics' Share-based Compensation fell 618.89% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 395.38%. This contributed to the annual value of $4.5 million for FY2024, which is 3353.86% down from last year.
  • According to the latest figures from Q3 2025, Lucid Diagnostics' Share-based Compensation is $1.2 million, which was down 618.89% from $1.1 million recorded in Q2 2025.
  • Lucid Diagnostics' 5-year Share-based Compensation high stood at $3.8 million for Q2 2022, and its period low was $933000.0 during Q1 2024.
  • For the 4-year period, Lucid Diagnostics' Share-based Compensation averaged around $2.0 million, with its median value being $1.2 million (2024).
  • As far as peak fluctuations go, Lucid Diagnostics' Share-based Compensation crashed by 7425.13% in 2023, and later skyrocketed by 2159.92% in 2024.
  • Quarter analysis of 4 years shows Lucid Diagnostics' Share-based Compensation stood at $3.7 million in 2022, then crashed by 74.25% to $963000.0 in 2023, then rose by 21.6% to $1.2 million in 2024, then dropped by 1.62% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $1.1 million for Q2 2025, and $1.0 million during Q1 2025.